Optimizing HIV testing: Comparing diagnostic signatures and assay performance in ART-treated and general screening populations
- 21 February 2025
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 570, 120207
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Suppressed HIV antibody responses following exposure to antiretrovirals—evidence from PrEP randomized trials and early antiretroviral treatment initiation studiesInternational Journal of Infectious Diseases, 2024
- HIV acute infection and long-term undisclosed HIV status among blood donors from the highly endemic Amazonas state, located in the Brazilian AmazonThe Brazilian Journal of Infectious Diseases, 2024
- HIV Infection — Screening, Diagnosis, and TreatmentNew England Journal of Medicine, 2021
- Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern ChinaVirologica Sinica, 2019
- Relevance of cutoff on a 4th generation ELISA performance in the false positive rate during HIV diagnostic in a low HIV prevalence settingJournal of Clinical Virology, 2017
- Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV SerologyClinical Infectious Diseases, 2016
- Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasmaJournal of Clinical Virology, 2011
- Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo AssayJournal of Clinical Virology, 2011
- Persistent Low‐Level Viremia in HIV‐1 Elite Controllers and Relationship to Immunologic ParametersThe Journal of Infectious Diseases, 2009
- Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute/Early HIV InfectionClinical Infectious Diseases, 2006